Skip to main content

2017 Parkinson's Research Year in Review

December 14, 2017

In this webinar, we cover advances in our understanding of Parkinson's disease and development of new treatments.

Webinar Details


Thursday, December 14, 2017


1 hr


12:00 pm ET

  • MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: December 14, 2017
    Date CME Credit No Longer Available: December 14, 2019

    Learning Objectives

    At the conclusion of this course, participants should be able to: 

    • Discuss disease-modifying therapies in clinical trials for Parkinson's disease, including repurposed drugs and novel therapies targeting genetic mutations. 
    • Summarize progress in Parkinson's symptomatic therapies, including recently approved drugs and therapies in clinical trials to treat motor and non-motor symptoms. 
    • Identify advances in disease understandings and describe how these are leading toward new treatment approaches and more efficient trials.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Andrew Siderowf, MD
    Director, Parkinson Disease Movement Disorder Center
    University of Pennsylvania
    Disclosures: Advisory Role, Voyager; Former Employee, Eli Lilly and Co.; Independent Contractor, Biogen and Wave

    Todd Sherer, PhD
    Chief Executive Officer 
    The Michael J. Fox Foundation
    Wife employed at Pfizer

    Dave Iverson
    Nothing to disclose

    Douglas DuMond
    Person with Parkinson's
    Nothing to disclose

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.